Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zolgensma (onasemnogene abeparvovec)
Pharma
Novartis readies intrathecal Zolgensma for older SMA patients
FDA filing for intrathecal Zolgensma is planned for first-half 2025 after a positive phase 3 readout.
Angus Liu
Jan 2, 2025 12:30pm
BMS takes over Novartis' gene therapy plant in Illinois
Apr 26, 2023 10:25am
Performance slump takes toll on Novartis' CEO's 2022 payout
Mar 8, 2023 9:33am
Biogen's new CEO looks to ads to boost new drugs
Feb 16, 2023 9:10am
Novartis delays Pluvicto filing after FDA requests more data
Feb 1, 2023 11:19am
EMA looks to warn doctors of Zolgensma's liver failure deaths
Jan 13, 2023 11:02am
